Department of Internal Medicine Liver Research InstituteSeoul National University College of Medicine Seoul Republic of Korea.
Department of Statistics and Actuarial Science Soongsil University Seoul Republic of Korea.
J Am Heart Assoc. 2021 Jan 5;10(1):e017783. doi: 10.1161/JAHA.120.017783. Epub 2020 Dec 29.
Background Although occult hemoglobin in feces is universally valued as a screening tool for colorectal cancer (CRC), only few studies investigated the clinical meaning of fecal immunochemical test (FIT) in other diseases. We evaluated the clinical utility of FIT in patients with cardiovascular diseases (namely, ischemic stroke and myocardial infarction [MI]). Methods and Results Using the National Health Insurance database, participants (aged >50 years) with CRC screening records from 2009 to 2012 were screened and followed up. Subjects with a history of cardiovascular diseases and CRC were excluded. Ischemic stroke, MI, and other comorbidities were defined by (), codes. Age, sex, smoking, alcohol consumption, regular exercise, diabetes mellitus, hypertension, dyslipidemia, and body mass index were adjusted in a multivariate analysis. A total of 6 277 446 subjects were eligible for analysis. During the mean 6.79 years of follow-up, 168 570 participants developed ischemic stroke, 105 983 developed MI, and 11 253 deaths were observed. A multivariate-adjusted model revealed that the risk of ischemic stroke was higher in the FIT-positive population (adjusted hazard ratio [HR], 1.09; 95% CI, 1.07-1.11). Similarly, FIT-positive subjects were at an increased risk of MI (adjusted HR, 1.09; 95% CI, 1.06-1.12). Moreover, increased all-cause mortality was observed in the FIT-positive population (adjusted HR, 1.15; 95% CI, 1.07-1.23). The increased risk remained consistent in the stratified analysis on anemia and CRC status. Conclusions Positive FIT findings were associated with ischemic stroke, MI, and mortality. Occult blood in feces may offer more clinical information than its well-known conventional role in CRC screening.
尽管粪便隐血普遍被认为是结直肠癌(CRC)筛查的工具,但只有少数研究调查了粪便免疫化学检测(FIT)在其他疾病中的临床意义。我们评估了 FIT 在患有心血管疾病(即缺血性卒中和心肌梗死[MI])患者中的临床应用价值。
使用国家健康保险数据库,筛选了 2009 年至 2012 年有 CRC 筛查记录的参与者(年龄>50 岁),并进行了随访。排除有心血管疾病和 CRC 病史的患者。缺血性卒中、MI 和其他合并症通过 ICD-10 编码定义。在多变量分析中调整了年龄、性别、吸烟、饮酒、规律运动、糖尿病、高血压、血脂异常和体重指数。共有 6277446 名符合条件的患者进行了分析。在平均 6.79 年的随访期间,168570 名患者发生缺血性卒中,105983 名患者发生 MI,11253 名患者死亡。多变量调整模型显示,FIT 阳性人群发生缺血性卒中的风险较高(调整后的危险比[HR],1.09;95%可信区间[CI],1.07-1.11)。同样,FIT 阳性患者发生 MI 的风险增加(调整后的 HR,1.09;95% CI,1.06-1.12)。此外,FIT 阳性人群的全因死亡率增加(调整后的 HR,1.15;95% CI,1.07-1.23)。在对贫血和 CRC 状态进行的分层分析中,风险增加仍然一致。
FIT 阳性结果与缺血性卒中、MI 和死亡率相关。粪便潜血可能提供比其在 CRC 筛查中的传统作用更有价值的临床信息。